Search





Search





Markets
/
Stocks
/
nasdaq-ptct
/

PTC Therapeutics Inc

PTCT

Add to Watchlist

69.785USD

+1.095+1.59%

Market hours （ET）Quotes delayed by 15 min

1.65BMarket Cap

8.27P/E TTM



PTC Therapeutics Inc

69.785

+1.095+1.59%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of PTC Therapeutics Inc

Currency: USD Updated: 2026-04-10

Key Insights

PTC Therapeutics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 29 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 86.07.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

PTC Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

29 / 156

Overall Ranking

95 / 4527

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

PTC Therapeutics Inc Highlights

StrengthsRisks

PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 84.54% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 8.00, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 93.85M shares, increasing 1.00% quarter-over-quarter.

Held by Ray Dalio

Star Investor Ray Dalio holds 16.23K shares of this stock.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

86.067

Target Price

+21.48%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-04-10

The current financial score of PTC Therapeutics Inc is 7.14, ranking 121 out of 156 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 164.68M, representing a year-over-year decrease of 22.75%, while its net profit experienced a year-over-year decrease of 104.85%.

Score

Industry at a Glance

Previous score

7.14

Change



Financials

5.89

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.91

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.10

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.58

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.20

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

PTC Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-04-10

The current valuation score of PTC Therapeutics Inc is 8.42, ranking 18 out of 156 in the Pharmaceuticals industry. Its current P/E ratio is 8.00, which is 12.90% below the recent high of 9.04 and 251.10% above the recent low of -12.09.

Score

Industry at a Glance

Previous score

8.42

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 29/156

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-04-10

The current earnings forecast score of PTC Therapeutics Inc is 7.33, ranking 104 out of 156 in the Pharmaceuticals industry. The average price target is 80.00, with a high of 118.00 and a low of 55.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

86.067

Target Price

+21.48%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

PTC Therapeutics Inc

PTCT

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-04-10

The current price momentum score of PTC Therapeutics Inc is 8.77, ranking 56 out of 156 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 72.69 and the support level at 64.24, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.36

Change

-0.59

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

1.089

Neutral

RSI(14)

51.728

Neutral

STOCH(KDJ)(9,3,3)

68.762

Sell

ATR(14)

2.372

Low Volatility

CCI(14)

63.676

Neutral

Williams %R

43.083

Buy

TRIX(12,20)

0.118

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

69.856

Sell

MA10

68.570

Buy

MA20

67.422

Buy

MA50

68.756

Buy

MA100

72.857

Sell

MA200

64.936

Buy

Institutional Confidence

Currency: USD Updated: 2026-04-10

The current institutional shareholding score of PTC Therapeutics Inc is 10.00, ranking 1 out of 156 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 113.38%, representing a quarter-over-quarter increase of 6.01%. The largest institutional shareholder is The Vanguard, holding a total of 8.79M shares, representing 10.61% of shares outstanding, with 2.09% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

11.38M

+100.11%

The Vanguard Group, Inc.

Star Investors

8.79M

+6.21%

RTW Investments L.P.

7.75M

Janus Henderson Investors

4.85M

+28.56%

State Street Investment Management (US)

4.21M

+34.18%

Toronto-Dominion Bank

4.14M

TD Securities, Inc.

4.14M

+27.47%

Wellington Management Company, LLP

3.87M

-21.37%

Armistice Capital LLC

2.80M

-14.51%

Geode Capital Management, L.L.C.

2.02M

+3.34%

Risk Assessment

Currency: USD Updated: 2026-04-10

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of PTC Therapeutics Inc is 6.71, ranking 48 out of 156 in the Pharmaceuticals industry. The company's beta value is 0.62. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. PTC Therapeutics Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.